T3	Effect 0 34	Temporary neurologic abnormalities
T4	Subject 52 74	one out of 23 patients
T5	Treat-Disorder 140 158	osteogenic sarcoma
T6	Treatment 86 135	chemotherapy with high-dose methotrexate (HD-MTX)
T8	Population 52 65	one out of 23
T9	Dosage 104 113	high-dose
T10	Drug 114 126	methotrexate
